亚宝药业拟转让太原制药62%股权，提高公司资产运营效率

Core Viewpoint - The company plans to sell 62% of its subsidiary Taiyuan Pharmaceutical Co., Ltd. to Shanxi Tongxiang Times Technology Co., Ltd. for RMB 87.1887 million, which will result in a significant change in ownership structure and financial reporting [1][2] Group 1: Transaction Details - After the transaction, Shanxi Tongxiang will hold 95% of Taiyuan Pharmaceutical, while the company will retain 5%, leading to Taiyuan Pharmaceutical being excluded from the company's consolidated financial statements [1][2] - The transaction is based on an asset-based valuation method, with Taiyuan Pharmaceutical's net asset book value at RMB 54.1061 million and a total equity valuation of RMB 141 million, resulting in an appraisal increment of RMB 86.5209 million and an increase rate of 159.91% [1] Group 2: Financial Impact - The company anticipates that the transaction will increase its profit by approximately RMB 59 million for the fiscal year 2025, subject to final audited figures [1] - Taiyuan Pharmaceutical reported revenues of RMB 9.0671 million and RMB 390,400 for the years 2024 and January to August 2025, respectively, with net losses of RMB 15.3785 million and RMB 614,730 during the same periods [1] Group 3: Operational Changes - Employee placement at Taiyuan Pharmaceutical has been completed, and its management will be nominated by Shanxi Tongxiang after the transaction [2] - The company confirms that there are no guarantees or financial management arrangements involving Taiyuan Pharmaceutical, and there will be no related party transactions or competition issues post-transaction [2] Group 4: Company Performance - The company reported a third-quarter revenue of RMB 569 million, a year-on-year decrease of 16.01%, and a net profit of RMB 40.6971 million, down 26.22% [2] - For the first three quarters, the company achieved revenues of RMB 1.709 billion, a decline of 19.46%, and a net profit of RMB 215 million, down 8.44% [2]